Loading stock data…
Atossa Therapeutics (ATOS)
$1.98+0.10 (+5.32%)
Pre-Market$2.03+0.05 (+2.53%)· Last close Jun 29
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Atossa Therapeutics, Inc. in the Healthcare sector is trading at $1.98 with a market capitalization of $23M. Wall Street consensus targets $22.00 (3 analysts), implying a +1011.1% move over the next 12 months. The stock is currently near its 52-week low of $1.70, remaining 76.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1011.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 10) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.87M↑ | -$11.44M↓ | -$9.25M↓ | -$9.04M↓ | -$7.41M |
| Net Income | -$9.59M↑ | -$10.94M↓ | -$8.69M↓ | -$8.42M↓ | -$6.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modula...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-123.47%
Volume
Today's trading volume
180,458
Recent News
Top Midday Decliners
Oracle (ORCL) plans to raise about $40 billion via debt and equity issuances in fiscal 2027, includi
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment
Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company’s lead investigational therapy, (Z)-Endoxifen, and its potential applications across multiple breast cancer indications as well as certain rare diseases. The discussion highlighted the scientific foundation of the program, recent clinical data presentations, and key milestones expected in the months ahead. Quay explained that Atossa Therapeutics was founded with a clear mission focused on improving the prevention and treatment of breast cancer. Central to that strategy is the development of (Z)-Endoxifen, a therapy derived from decades of clinical experience and scientific understanding surrounding tamoxifen, one of the most widely prescribed treatments for hormone receptor-positive breast cancer. While tamoxifen has been a standard therapy for many years, its effectiveness depends on a patient’s ability to metabolize the drug into its active form, Endoxifen. Quay noted that this process can vary significantly between individuals due to genetic differences and metabolic factors. Atossa’s approach is to administer Endoxifen directly, potentially bypassing those limitations and providing more consistent therapeutic exposure across patients. According to Quay, clinical studies conducted to date have demonstrated encouraging signs of efficacy while maintaining what he described as a notably clean safety profile. The company believes the direct administration approach could offer meaningful advantages in both treatment and prevention settings. The CEO reviewed Atossa’s clinical progress, noting that the company has successfully completed multiple Phase 2 clinical trials evaluating Endoxifen in various breast cancer settings. These studies have generated data supporting the continued advancement of the program and helping to define potential pathways toward later-stage development. The findings presented at ASCO generated considerable interest, particularly data suggesting that Endoxifen may remain active in breast cancers that have developed mutations commonly associated with resistance to endocrine therapies. Resistance to hormonal treatments remains a significant challenge in breast cancer management, and the possibility of maintaining therapeutic activity in resistant tumors could represent an important clinical opportunity. Quay noted that feedback from oncologists, researchers, and industry participants at ASCO was highly encouraging, particularly regarding the potential implications of the resistance-related findings. Management believes these observations could help differentiate Endoxifen from existing treatment options and support future development strategies. Looking ahead, Atossa plans to consolidate results from multiple ongoing and completed clinical programs to build a comprehensive dataset supporting future regulatory discussions. The company intends to engage with regulatory authorities and potential pharmaceutical partners as it evaluates the most effective path toward Phase 3 clinical development and eventual commercialization. #proactiveinvestors #nasdaq #atos #BreastCancer #Endoxifen #Biotech #Oncology #ClinicalTrials #CancerResearch #ASCO #DrugDevelopment #HealthcareInnovation
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Strong Sell Stocks for Oct. 22
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...